CJM-112 is a humanized monoclonal antibody inhibitor that targets interleukin-17A (IL-17A). It holds potential for research in inflammatory diseases, such as hidradenitis suppurativa, which involve abnormalities in the IL-17A-related pathway.
Target-Kategorie:
Interleukin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
